Oleanolic acid: a novel cardioprotective agent that blunts hyperglycemia-induced contractile dysfunction.
Diabetes constitutes a major health challenge. Since cardiovascular complications are common in diabetic patients this will further increase the overall burden of disease. Furthermore, stress-induced hyperglycemia in non-diabetic patients with acute myocardial infarction is associated with higher in...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/0f9ff1a1307a43949df3689bfd4eac8a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:0f9ff1a1307a43949df3689bfd4eac8a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:0f9ff1a1307a43949df3689bfd4eac8a2021-11-18T08:11:50ZOleanolic acid: a novel cardioprotective agent that blunts hyperglycemia-induced contractile dysfunction.1932-620310.1371/journal.pone.0047322https://doaj.org/article/0f9ff1a1307a43949df3689bfd4eac8a2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23091615/?tool=EBIhttps://doaj.org/toc/1932-6203Diabetes constitutes a major health challenge. Since cardiovascular complications are common in diabetic patients this will further increase the overall burden of disease. Furthermore, stress-induced hyperglycemia in non-diabetic patients with acute myocardial infarction is associated with higher in-hospital mortality. Previous studies implicate oxidative stress, excessive flux through the hexosamine biosynthetic pathway (HBP) and a dysfunctional ubiquitin-proteasome system (UPS) as potential mediators of this process. Since oleanolic acid (OA; a clove extract) possesses antioxidant properties, we hypothesized that it attenuates acute and chronic hyperglycemia-mediated pathophysiologic molecular events (oxidative stress, apoptosis, HBP, UPS) and thereby improves contractile function in response to ischemia-reperfusion. We employed several experimental systems: 1) H9c2 cardiac myoblasts were exposed to 33 mM glucose for 48 hr vs. controls (5 mM glucose); and subsequently treated with two OA doses (20 and 50 µM) for 6 and 24 hr, respectively; 2) Isolated rat hearts were perfused ex vivo with Krebs-Henseleit buffer containing 33 mM glucose vs. controls (11 mM glucose) for 60 min, followed by 20 min global ischemia and 60 min reperfusion ± OA treatment; 3) In vivo coronary ligations were performed on streptozotocin treated rats ± OA administration during reperfusion; and 4) Effects of long-term OA treatment (2 weeks) on heart function was assessed in streptozotocin-treated rats. Our data demonstrate that OA treatment blunted high glucose-induced oxidative stress and apoptosis in heart cells. OA therapy also resulted in cardioprotection, i.e. for ex vivo and in vivo rat hearts exposed to ischemia-reperfusion under hyperglycemic conditions. In parallel, we found decreased oxidative stress, apoptosis, HBP flux and proteasomal activity following ischemia-reperfusion. Long-term OA treatment also improved heart function in streptozotocin-diabetic rats. These findings are promising since it may eventually result in novel therapeutic interventions to treat acute hyperglycemia (in non-diabetic patients) and diabetic patients with associated cardiovascular complications.Rudo F MapangaUthra RajamaniNonkululeko DlaminiMakhosazane Zungu-EdmondsonRoisin Kelly-LaubscherMohammed ShafiullahAthiq WahabMohamed Y HasanMohamed A FahimPhilippe RondeauEmmanuel BourdonM Faadiel EssopPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 10, p e47322 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Rudo F Mapanga Uthra Rajamani Nonkululeko Dlamini Makhosazane Zungu-Edmondson Roisin Kelly-Laubscher Mohammed Shafiullah Athiq Wahab Mohamed Y Hasan Mohamed A Fahim Philippe Rondeau Emmanuel Bourdon M Faadiel Essop Oleanolic acid: a novel cardioprotective agent that blunts hyperglycemia-induced contractile dysfunction. |
| description |
Diabetes constitutes a major health challenge. Since cardiovascular complications are common in diabetic patients this will further increase the overall burden of disease. Furthermore, stress-induced hyperglycemia in non-diabetic patients with acute myocardial infarction is associated with higher in-hospital mortality. Previous studies implicate oxidative stress, excessive flux through the hexosamine biosynthetic pathway (HBP) and a dysfunctional ubiquitin-proteasome system (UPS) as potential mediators of this process. Since oleanolic acid (OA; a clove extract) possesses antioxidant properties, we hypothesized that it attenuates acute and chronic hyperglycemia-mediated pathophysiologic molecular events (oxidative stress, apoptosis, HBP, UPS) and thereby improves contractile function in response to ischemia-reperfusion. We employed several experimental systems: 1) H9c2 cardiac myoblasts were exposed to 33 mM glucose for 48 hr vs. controls (5 mM glucose); and subsequently treated with two OA doses (20 and 50 µM) for 6 and 24 hr, respectively; 2) Isolated rat hearts were perfused ex vivo with Krebs-Henseleit buffer containing 33 mM glucose vs. controls (11 mM glucose) for 60 min, followed by 20 min global ischemia and 60 min reperfusion ± OA treatment; 3) In vivo coronary ligations were performed on streptozotocin treated rats ± OA administration during reperfusion; and 4) Effects of long-term OA treatment (2 weeks) on heart function was assessed in streptozotocin-treated rats. Our data demonstrate that OA treatment blunted high glucose-induced oxidative stress and apoptosis in heart cells. OA therapy also resulted in cardioprotection, i.e. for ex vivo and in vivo rat hearts exposed to ischemia-reperfusion under hyperglycemic conditions. In parallel, we found decreased oxidative stress, apoptosis, HBP flux and proteasomal activity following ischemia-reperfusion. Long-term OA treatment also improved heart function in streptozotocin-diabetic rats. These findings are promising since it may eventually result in novel therapeutic interventions to treat acute hyperglycemia (in non-diabetic patients) and diabetic patients with associated cardiovascular complications. |
| format |
article |
| author |
Rudo F Mapanga Uthra Rajamani Nonkululeko Dlamini Makhosazane Zungu-Edmondson Roisin Kelly-Laubscher Mohammed Shafiullah Athiq Wahab Mohamed Y Hasan Mohamed A Fahim Philippe Rondeau Emmanuel Bourdon M Faadiel Essop |
| author_facet |
Rudo F Mapanga Uthra Rajamani Nonkululeko Dlamini Makhosazane Zungu-Edmondson Roisin Kelly-Laubscher Mohammed Shafiullah Athiq Wahab Mohamed Y Hasan Mohamed A Fahim Philippe Rondeau Emmanuel Bourdon M Faadiel Essop |
| author_sort |
Rudo F Mapanga |
| title |
Oleanolic acid: a novel cardioprotective agent that blunts hyperglycemia-induced contractile dysfunction. |
| title_short |
Oleanolic acid: a novel cardioprotective agent that blunts hyperglycemia-induced contractile dysfunction. |
| title_full |
Oleanolic acid: a novel cardioprotective agent that blunts hyperglycemia-induced contractile dysfunction. |
| title_fullStr |
Oleanolic acid: a novel cardioprotective agent that blunts hyperglycemia-induced contractile dysfunction. |
| title_full_unstemmed |
Oleanolic acid: a novel cardioprotective agent that blunts hyperglycemia-induced contractile dysfunction. |
| title_sort |
oleanolic acid: a novel cardioprotective agent that blunts hyperglycemia-induced contractile dysfunction. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2012 |
| url |
https://doaj.org/article/0f9ff1a1307a43949df3689bfd4eac8a |
| work_keys_str_mv |
AT rudofmapanga oleanolicacidanovelcardioprotectiveagentthatbluntshyperglycemiainducedcontractiledysfunction AT uthrarajamani oleanolicacidanovelcardioprotectiveagentthatbluntshyperglycemiainducedcontractiledysfunction AT nonkululekodlamini oleanolicacidanovelcardioprotectiveagentthatbluntshyperglycemiainducedcontractiledysfunction AT makhosazanezunguedmondson oleanolicacidanovelcardioprotectiveagentthatbluntshyperglycemiainducedcontractiledysfunction AT roisinkellylaubscher oleanolicacidanovelcardioprotectiveagentthatbluntshyperglycemiainducedcontractiledysfunction AT mohammedshafiullah oleanolicacidanovelcardioprotectiveagentthatbluntshyperglycemiainducedcontractiledysfunction AT athiqwahab oleanolicacidanovelcardioprotectiveagentthatbluntshyperglycemiainducedcontractiledysfunction AT mohamedyhasan oleanolicacidanovelcardioprotectiveagentthatbluntshyperglycemiainducedcontractiledysfunction AT mohamedafahim oleanolicacidanovelcardioprotectiveagentthatbluntshyperglycemiainducedcontractiledysfunction AT philipperondeau oleanolicacidanovelcardioprotectiveagentthatbluntshyperglycemiainducedcontractiledysfunction AT emmanuelbourdon oleanolicacidanovelcardioprotectiveagentthatbluntshyperglycemiainducedcontractiledysfunction AT mfaadielessop oleanolicacidanovelcardioprotectiveagentthatbluntshyperglycemiainducedcontractiledysfunction |
| _version_ |
1718422027224743936 |